- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00162123
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
28. června 2016 aktualizováno: Bristol-Myers Squibb
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment.
In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.
Přehled studie
Typ studie
Intervenční
Zápis (Aktuální)
248
Fáze
- Fáze 2
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
-
Buenos Aires, Argentina, CP1280AEB
- Local Institution
-
-
-
-
-
Brussels, Belgie, 1090
- Local Institution
-
Brussels, Belgie, 1070
- Local Institution
-
Bruxelles, Belgie, 1200
- Local Institution
-
-
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazílie, 90610
- Local Institution
-
Porto Alegre, Rio Grande Do Sul, Brazílie, 90050
- Local Institution
-
-
Sao Paulo
-
Jau, Sao Paulo, Brazílie, 17210
- Local Institution
-
-
-
-
-
Aarhus C, Dánsko, 8000
- Local Institution
-
-
-
-
-
Brest, Francie, 29200
- Local Institution
-
Lyon Cedex 08, Francie, 69373
- Local Institution
-
Paris, Francie, 75010
- Local Institution
-
Vandoeuvre Les Nancy, Francie, 54511
- Local Institution
-
-
-
-
-
Genova, Itálie, 16132
- Local Institution
-
Meldola (Fc), Itálie, 47014
- Local Institution
-
Rimini, Itálie, 47900
- Local Institution
-
Siena, Itálie, 53100
- Local Institution
-
-
-
-
-
Jerusalem, Izrael, 91120
- Local Institution
-
Tel-Aviv, Izrael, 64239
- Local Institution
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Jižní Afrika, 2199
- Local Institution
-
-
Western Cape
-
Cape Town, Western Cape, Jižní Afrika, 7570
- Local Institution
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 4N2
- Local Institution
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Local Institution
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1C 6Z8
- Local Institution
-
-
-
-
-
Oslo, Norsko, 0310
- Local Institution
-
-
-
-
-
Berlin, Německo, D-12200
- Local Institution
-
Heidelberg, Německo, 69120
- Local Institution
-
Kiel, Německo, D-24105
- Local Institution
-
-
-
-
-
Lodz, Polsko, 90553
- Local Institution
-
Poznan, Polsko, 61-866
- Local Institution
-
Wroclaw, Polsko, 51-124
- Local Institution
-
-
-
-
-
Wels, Rakousko, A-4600
- Local Institution
-
Wien, Rakousko, 1090
- Local Institution
-
-
-
-
-
St. Petersburg, Ruská Federace, 191104
- Local Institution
-
Stavropol, Ruská Federace, 355047
- Local Institution
-
Voronezh, Ruská Federace, 394000
- Local Institution
-
-
-
-
Arizona
-
Tucson, Arizona, Spojené státy, 85719
- University of Arizona Cancer Center
-
-
California
-
Laverne, California, Spojené státy, 91750
- Wilshire Oncology Medical Group Inc
-
Los Angeles, California, Spojené státy, 90033
- USC/Norris Comprehensive Cancer Center
-
Los Angeles, California, Spojené státy, 90025
- The Angeles Clinic & Research Inst.
-
San Francisco, California, Spojené státy, 94115
- San Francisco Oncology Associates
-
-
Connecticut
-
To come, Connecticut, Spojené státy
- Local Institution
-
-
Florida
-
Jacksonville, Florida, Spojené státy, 32207
- Baptist Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Indiana Oncology Hematology Consultants
-
-
Missouri
-
Saint Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
St Joseph, Missouri, Spojené státy, 64507
- St Joseph Oncology Inc
-
-
New York
-
New York, New York, Spojené státy, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Spojené státy, 28203
- Carolinas Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45219
- The Christ Hospital Cancer Center Research
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97213
- Providence Portland Medical Center
-
-
South Carolina
-
Greenville, South Carolina, Spojené státy, 29615
- Cancer Centers of the Carolinas
-
-
Texas
-
Dallas, Texas, Spojené státy, 75230
- Center For Oncology Research & Treatment, P.A.
-
Lubbock, Texas, Spojené státy, 79410
- Joe Arrington Cancer Research and Treatment Center
-
-
Washington
-
Seattle, Washington, Spojené státy, 98109
- University of Washington Medical Center
-
-
-
-
-
Dnepropetrovsk, Ukrajina, 49044
- Local Institution
-
-
-
-
-
Olomouc, Česká republika, 775 20
- Local Institution
-
-
-
-
-
Malaga, Španělsko, 29010
- Local Institution
-
Valencia, Španělsko, 46009
- Local Institution
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let a starší (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Key Inclusion Criteria
- Diagnosis of advanced melanoma
- Prior treatment in a prespecified prior/parent ipilimumab study
- Men and women 18 years of age and older
First Reinduction:
- No unacceptable toxicity (except select reversible immune-related adverse events) requiring ipilimumab discontinuation
- Had experienced documented progressive disease after expanded clinical benefit
Extended Maintenance
- Received ipilimumab at any dose in a parent study
- Achieved expanded clinical benefit at the time of entry to current study
Follow-up:
- Received ipilimumab at any dose in a closing parent study
- Deemed ineligible for reinduction or extended maintenance treatment or refused treatment as reinduction or extended maintenance at the time of screening in the current study, but consented to follow-up
Key Exclusion Criteria
- Prior treatment with a CD137 agonist or a cytotoxic T-lymphocyte antigen 4 inhibitor or agonist, other than ipilimumab
- Primary ocular or mucosal melanoma
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: First reinduction: Ipilimumab, 0.3 to 10 mg/kg
Participants who initially received ipilimumab, 0.3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Ostatní jména:
|
|
Experimentální: First reinduction: Ipilimumab, 3 to 10 mg/kg
Participants who initially received ipilimumab, 3 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Ostatní jména:
|
|
Experimentální: First reinduction: Ipilimumab, 10 to 10 mg/kg
Participants who initially received ipilimumab, 10 mg/kg, in a parent study received ipilimumab, 10 mg/kg in the current study.
Ipilimumab was administered as an individual open-label dose every 3 weeks for the first 10 weeks of reinduction for a total of 4 separate doses unless the patient experienced disease progression or withdrew consent.
Participants had to wait 3 weeks from the last dose of ipilimumab in a parent study to the first dose of ipilimumab in the current study.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Ostatní jména:
|
|
Experimentální: Extended maintenance: Ipilimumab, 0.3 mg/kg
Participants who received ipilimumab, 0.3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (0.3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Ostatní jména:
|
|
Experimentální: Extended maintenance: Ipilimumab, 3 mg/kg
Participants who received ipilimumab, 3 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (3 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Ostatní jména:
|
|
Experimentální: Extended maintenance: Ipilimumab, 10 mg
Participants who received ipilimumab, 10 mg/kg, in a parent study and who achieved extended clinical benefit received the same dose of ipilimumab (10 mg/kg) as maintenance in the current study.
Maintenance dosing was administered every 12 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
|
Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
Ostatní jména:
|
|
Žádný zásah: Follow-up
Participants did not receive any additional study treatment in current study but continued follow-up for the collection of survival data.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants With On-study Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related AEs, Immune-related AEs (irAEs), and Death as Outcome
Časové okno: Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
An SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Drug-related is defined as having certain, probable, possible, or missing relationship to study drug.
An IrAE is an AE characterized by a potential association with inflammation and considered by the investigator to be drug related.
Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death.
|
Continuously from first dose to 70 days after last dose of study drug. For deaths, Day 1 of enrollment to 70 days after last dose of study drug.
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Overall Survival (OS)
Časové okno: From first dose of study drug in parent study to death or date of last censoring.
|
OS was computed for all patients who entered this study and is defined as the time between the first dose of study therapy and death.
If a patient has not died, OS was censored at the time of last contact.
|
From first dose of study drug in parent study to death or date of last censoring.
|
|
Percentage of Participants Surviving at 1, 1.5, and 2 Years
Časové okno: From first dose of study drug in parent study to up to 2 years after reinduction
|
Survival rate was defined as the time from first dose of study drug to 1, 1.5, and 2 years.
|
From first dose of study drug in parent study to up to 2 years after reinduction
|
|
Number of Participants With On-study Immune-related Adverse Events (irAEs)
Časové okno: From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
irAEs were defined as adverse events characterized by a potential association with inflammation and considered by the investigator as drug related.
These prespecified terms were grouped into the following organ-specific subcategories: gastrointestinal, hepatic, skin, endocrine, neurologic, and other (includes blood, eye, immune system, investigations, infections, renal, and respiratory systems).
Patients may have 1 or more events.
|
From first dose of study drug during reinduction to the earliest of 70 days after last dose or day before second reinduction first dose date
|
|
Progression-free Survival (PFS)
Časové okno: From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
PFS was defined as the time between the date of the baseline tumor assessment in this study and the date of progression or death, whichever occurred first.
|
From day of first reinduction in current study to date of progression or death, whichever occurred first.
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Užitečné odkazy
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. května 2006
Primární dokončení (Aktuální)
1. září 2012
Dokončení studie (Aktuální)
1. dubna 2014
Termíny zápisu do studia
První předloženo
9. září 2005
První předloženo, které splnilo kritéria kontroly kvality
9. září 2005
První zveřejněno (Odhad)
13. září 2005
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
27. července 2016
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
28. června 2016
Naposledy ověřeno
1. června 2016
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Novotvary podle histologického typu
- Novotvary
- Neuroektodermální nádory
- Novotvary, zárodečné buňky a embryonální
- Novotvary, nervová tkáň
- Neuroendokrinní nádory
- Nevi a melanomy
- Melanom
- Molekulární mechanismy farmakologického působení
- Antineoplastická činidla
- Antineoplastická činidla, Imunologická
- Inhibitory imunitního kontrolního bodu
- Ipilimumab
Další identifikační čísla studie
- CA184-025
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .